A bipartisan Senate bill introduced by Senators James Lankford (R-OK) and Maggie Hassan (D-NH) seeks to lower prescription drug costs for Medicare beneficiaries by reforming how Part D plans cover generics and biosimilars. The Ensuring Access to Lower-Cost Medicines for Seniors Act would require Medicare Part D plans to include cheaper generic drugs when available and ensure at least one lower-cost biosimilar is covered when a reference biologic is on the formulary. The changes would take effect starting January 1, 2028.
Core Facts & Immediate Action
The bill aims to address pricing practices that sometimes result in higher out-of-pocket costs for seniors despite cheaper alternatives being available. For example, a generic insulin might cost more than its brand-name counterpart due to pharmacy benefit manager (PBM) rebates. The legislation would eliminate such pricing "gimmicks" by mandating that lower-cost generics and biosimilars are prioritized in Medicare Part D formularies.
Deeper Dive & Context
Policy Details
The bill would amend the Social Security Act to impose new requirements on Medicare Part D and Medicare Advantage plans. It specifies that starting in 2028, Part D formularies must include generic drugs when they are cheaper than brand-name drugs. Similarly, at least one lower-cost biosimilar must be included when a reference biologic is covered and a cheaper biosimilar is available.
Stakeholder Perspectives
Supporters argue the bill will prevent seniors from paying higher costs due to flawed pricing practices. Michael Ryan, a finance expert, told Newsweek that the legislation would eliminate confusion and ensure patients pay less for medications. Senator Lankford emphasized that the bill addresses a broken system where generic drugs are not always cheaper at the pharmacy counter.
Broader Healthcare Costs
The bill comes amid rising healthcare costs, with prescription drugs contributing significantly to premium increases. Mercer projects that average total health benefit costs per employee will rise by 6.5% in 2026, the largest increase in over a decade. Drug prices are a major factor in these costs, with more than 24 cents of every premium dollar going toward prescription medications.
Patent Reform Debate
Some critics argue that patent reform is needed to address drug manufacturers' practices of extending monopolies beyond what Congress intended. The Washington Examiner highlights that while bipartisan solutions exist, lawmakers must act quickly to provide relief to patients facing high drug prices.
Long-Term Implications
If passed, the bill could impact approximately 56 million Medicare Part D enrollees by ensuring they have access to lower-cost medications. The legislation also aligns with broader efforts to increase transparency and accountability in drug pricing practices.